KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Number Needed to Treat and Cost Per Responder Analysis of Anti-CGRP Monoclonal Antibodies for Migraine Prevention in Adults for Whom Prior Preventive Treatments have Failed.

Dimos D Mitsikostas, Susanne F Awad, Rikke Kongerslev, Line Pickering Boserup, Xin Ying Lee, Ravinder Phul, Simona Sacco

Adv Ther 42(11) 5742-5760

PMID40986186
PMCIDPMC12579663
DOI10.1007/s12325-025-03348-8
发表日期2025-09-23
入排依据:未发现恶性肿瘤人群证据。
已检查 6 张 PubMed Figure,均未识别为 KM 图:Fig. 1:AI 判定为 other;Fig. 2:AI 判定为 other;Fig. 3:AI 判定为 other;Fig. 4:AI 判定为 other;Fig. 5:AI 判定为 other;另有 1 张未列出。
摘要

摘要

INTRODUCTION: Four monoclonal antibodies (mAbs) targeting calcitonin gene-related peptide (CGRP) signaling are approved for migraine prevention and commonly prescribed/reimbursed after the failure of repurposed anti-migraine medications. Participants achieving clinical response [e.g., ≥ 50% monthly migraine days (MMDs) reduction] during an anti-CGRP mAb trial are likely to continue treatment. We calculated number needed to treat (NNT) and quarterly cost per responder (CPR) across four anti-CGRP mAbs. METHODS: Data were from randomized, double-blind, placebo-controlled phase 3b clinical trials that evaluated anti-CGRP mAbs (eptinezumab, fremanezumab, galcanezumab, erenumab) for migraine prevention in adults with episodic or chronic migraine for whom 2-4 prior preventive treatments have failed. NNT was calculated as 1 divided by absolute risk reduction (difference between active treatment and placebo in the proportion of participants with ≥ 50% or ≥ 75% MMD reduction over Weeks 1-12). CPR was calculated by multiplying NNT by the quarterly (3-month) drug acquisition CPR (£), based on the reimbursed list price in the United Kingdom (CPR could not be calculated for eptinezumab 300 mg). Statistical comparisons were not made. RESULTS: All anti-CGRP mAbs demonstrated higher rates of ≥ 50% and ≥ 75% MMD reduction than their respective placebo (p < 0.05). The NNT to achieve ≥ 50% MMD reduction ranged from 2.7 (eptinezumab 300 mg) to 6.0 (erenumab 140 mg), and for ≥ 75%, 6.0 (eptinezumab 300 mg) to 16.2 (fremanezumab 675 mg/q). The cost per ≥ 50% responder ranged from £4647 (eptinezumab 100 mg) to £7009 (erenumab 140 mg), and for ≥ 75%, £9850 (eptinezumab 100 mg) to £21,862 (fremanezumab 675 mg/q). CONCLUSIONS: These results show that, for most anti-CGRP mAbs, a low number of participants (< 10) with migraine need to be treated to achieve one person with a ≥ 50% or ≥ 75% reduction in MMDs over Weeks 1-12, with CPR ranging from £4647 (eptinezumab 100 mg) to £21,862 (fremanezumab 675 mg/q).

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(6,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Fig. 1 Migraine responder rates (MRRs) ≥ 50% over Weeks 1–12 or Weeks 9–12 for each anti-CGRP mAb in participants with EM or CM for whom 2–4 prior treatments had failed. MRRs were assessed over Weeks 1–12 in all trials except for LIBERTY, in which they were assessed over Weeks 9–12, the most comparable timepoint; p < 0.05 for each anti-CGRP mAb versus each respective placebo. CGRP calcitonin gene-related peptide, CM chronic migraine, EM episodic migraine, m month, mAb monoclonal antibody, mg milligram, MMD monthly migraine day, n number of participants with ≥ 50% reduction in monthly migraine days, N number of participants randomized to indicated trial arm, NR value not reported in primary publication, PBO placebo, q quarter
非 KM Figure
Fig. 2Fig. 2 Migraine responder rates (MRRs) ≥ 75% over Weeks 1–12 or Weeks 9–12 for each anti-CGRP mAb in participants with EM or CM for whom 2–4 prior treatments had failed. MRRs were assessed over Weeks 1–12 in all trials except for LIBERTY, in which they were assessed over Weeks 9–12, the most comparable timepoint; p < 0.05 for each anti-CGRP mAb versus each respective placebo. CGRP calcitonin gene-related peptide, CM chronic migraine, EM episodic migraine, m month, mAb monoclonal antibody, mg milligram, MMD monthly migraine day, n number of participants with ≥ 75% reduction in monthly migraine days, N number of participants randomized to indicated trial arm, NR value not reported in primary publication, PBO placebo, q quarter
非 KM Figure
Fig. 3Fig. 3 Number needed to treat ( NNT ) to achieve one person with ≥ 50% migraine response over Weeks 1–12 or Weeks 9–12 for each anti-CGRP mAb in participants with EM or CM for whom 2–4 prior treatments had failed. CGRP calcitonin gene-related peptide, CM chronic migraine, EM episodic migraine, m month, mAb monoclonal antibody, mg milligram, q quarter
非 KM Figure
Fig. 4Fig. 4 Number needed to treat ( NNT ) to achieve one person with ≥ 75% migraine response over Weeks 1–12 or Weeks 9–12 for each anti-CGRP mAb in participants with EM or CM for whom 2–4 prior treatments had failed. CGRP calcitonin gene-related peptide, CM chronic migraine, EM episodic migraine, m month, mAb monoclonal antibody, mg milligram, q quarter
非 KM Figure
Fig. 5Fig. 5 Quarterly cost per ≥ 50% migraine responder for each anti-CGRP mAb in participants with EM or CM for whom 2–4 prior treatments had failed. Costs per responder were calculated based on 2023 quarterly list prices for drug doses reimbursed in the UK. As of the date of publication, eptinezumab 300 mg is not reimbursed in the UK and was thus not included in this analysis. CGRP calcitonin gene-related peptide, CM chronic migraine, EM episodic migraine, m month, mAb monoclonal antibody, mg milligram, q quarter, UK United Kingdom
非 KM Figure
Fig. 6Fig. 6 Quarterly cost per ≥ 75% migraine responder for each anti-CGRP mAb in participants with EM or CM for whom 2–4 prior treatments had failed. Costs per responder were calculated based on the 2023 quarterly list price for drug doses reimbursed in the UK. As of the date of publication, eptinezumab 300 mg is not reimbursed in the UK and was thus not included in this analysis. CGRP calcitonin-related gene peptide, CM chronic migraine, EM episodic migraine, m month, mAb monoclonal antibody, mg milligram, q quarter, UK United Kingdom
非 KM Figure